Search | Clinical Trials Finder

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Magnetic Resonance Imaging, Bicycle Ergometry, Lab Panel, Questionnaires; Other · Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 8 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: Canakinumab, Pembrolizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: La Jolla, California • Kansas City, Kansas • Syracuse, New York + 1 more

Conditions: Severe Sepsis
Interventions: Not listed
Lead sponsor: Bluejay Diagnostics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Acton, Texas

Conditions: Multiple Myeloma
Interventions: Siltuximab, Dexamethasone; Biological · Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Duarte, California • Norwalk, Connecticut • Indianapolis, Indiana + 6 more

Conditions: Obesity, Diabetes, Hypertension, Hyperlipidemia
Interventions: Exercise, Reduced Calorie Diet, Weight Maintenance Diet; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 65 Years and older
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lung Cancer
Interventions: Cemiplimab, Kevzara (Sarilumab); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib), Melphalan, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Multiple Myeloma
Interventions: Siltuximab, Bortezomib, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 11
States / cities: Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more

Conditions: Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions: Clazakizumab; Drug
Lead sponsor: Stanley Jordan, MD; Other
Eligibility: 15 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19
Interventions: Clazakizumab; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis
Interventions: Lab Collection Only; Other
Lead sponsor: Scipher Medicine; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Whittier, California

Conditions: Sepsis, Septic Shock
Interventions: Not listed
Lead sponsor: Bluejay Diagnostics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Gainesville, Florida • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more

Conditions: Living-Donor Kidney Transplant, Kidney Transplant Recipients
Interventions: lulizumab pegol, antithymocyte globulin (rabbit), methylprednisolone, tocilizumab, Prednisone, everolimus, belatacept, mycophenolate mofetil, mycophenolic acid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 4 more

Conditions: Cancer, Prostate
Interventions: Mitoxantrone, Siltuximab, Prednisone; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 11
States / cities: Norwalk, Connecticut • Port Saint Lucie, Florida • Atlanta, Georgia + 8 more

Conditions: COVID-19
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 62
States / cities: Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more

Conditions: Malignant Pleural Effusion, Malignant Ascites
Interventions: Tocilizumab; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Arthritis, Rheumatoid
Interventions: Placebo, Sirukumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 48
States / cities: Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 45 more

Conditions: Imaging Techniques
Interventions: Xenon MRI, Pulmonary Function Testing, Quality of Life Questionnaire, Medical Research Council Dyspnea score, St. George's Respiratory Questionnaire, Blood Biomarkers; Drug · Diagnostic Test · Other
Lead sponsor: Sean Fain; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Calciphylaxis
Interventions: Tocilizumab; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arthritis, Rheumatoid
Interventions: CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg, Placebo, Methotrexate; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more

Conditions: Crohn's Disease
Interventions: Semapimod, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more

Conditions: Severe Sepsis
Interventions: Not listed
Lead sponsor: Bluejay Diagnostics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Acton, Texas

Conditions: Perioperative Inflammatory Response
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Exercise Intolerance and Skeletal Muscle Bioenergetics in Children With Deep Venous Thrombosis

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study

Treg Modulation With CD28 and IL-6 Receptor Antagonists

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

Using Xe MRI to Guide Radiation Therapy for Lung Cancer

Anti-Interleukin-6 (IL6) in Calciphylaxis

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo

Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis

Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery